<DOC>
	<DOCNO>NCT02506803</DOCNO>
	<brief_summary>Gemcitabine plus nub-paclitaxel ( GEMABR ) regimen recently present international oncology meeting represent new standard regimen treatment metastatic pancreatic cancer . Therefore , decide consider balance safety efficacy preoperative chemotherapy , investigator use NAC-GEMABR regimen include two cycle ( three time weekly one week rest ) GEMABR regimen .</brief_summary>
	<brief_title>Phase I Study Neoadjuvant Chemotherapy Patients With Borderline Resectable Pancreatic Cancer .</brief_title>
	<detailed_description>Gemcitabine plus nub-paclitaxel ( GEMABR ) regimen recently present international oncology meeting represent new standard regimen treatment metastatic pancreatic cancer . GEMABR one high response rate treatment regimen , investigator consider promising treatment neoadjuvant chemotherapy . On hand , incidence grade 3 4 neutropenia , febrile neutropenia peripheral neuropathy significantly high g group compare gemcitabine group . Therefore , decide consider balance safety efficacy preoperative chemotherapy , investigator use NAC-GEMABR regimen include two cycle ( three time weekly one week rest ) GEMABR regimen . The investigator also evaluate optimal treatment schedule NAC-GEMABR therapy neoadjuvant chemotherapy , optimal duration surgery chemotherapy , R0 resection rate , resection rate borderline resectable pancreatic cancer .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Pathologically proven invasive pancreatic ductal carcinoma Cases meet definition borderline resectable pancreatic cancer 1 ) 2 ) 1 . Definition borderline resectable pancreatic cancer filledin NCCN guideline version 1.2014 pancreatic adenocarcinoma 2 . Patients indicate distal pancreatectomy en bloc celiac axis resection PS ( ECOG ) 01 ≧20 year old &lt; 80 year old First line treatment The following criterion must satisfy laboratory test within 14 day registration White blood cell count ≦12,000/mm3 Neutrophil count ≧1,500/mm3 Platelet count ≧100,000mm3 Total bilirubin ＜2.0mg/dL Serum Creatinine ≦upper limit normal ( ULN ) AST , ALT≦2.5×ULN Albumin≧3.0g/dL Hemoglobin≧9.0g/dL Written inform consent participate study Severe drug hypersensitivity Multiple primary cancer within 5 year Severe infection With grade2 severe peripheral neuropathy With intestinal paralysys , ileus Interstitial pneumonia pulmonary With uncontrollable pleural effusion ascites Receiving atazanavir sulfate With uncontrollable diabetes With uncontrollable heart failure , angina , hypertension , arrhythmia With severe psychological symptom With watery diarrhea Pregnant lactate woman , woman know suspected pregnancy Inappropriate patient entry study judgment investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>